UMAX Group Corp. (UMAX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
UMAX Group Corp. (UMAX) trades at $0.0001 with AI Score 40/100 (Grade C). UMAX Group Corp. , operating as UMAX Nutrition, is a development stage company focused on natural and organic nutrition and dietary supplements. Sector: Financial services.
Price as of Aug 20, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for UMAX: UMAX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UMAX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
UMAX: 3/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
UMAX Group Corp. (UMAX) Financial Services Profile
UMAX Group Corp., operating as UMAX Nutrition, is a development stage company in the nutritional supplement industry. It focuses on developing and distributing natural and organic nutrition products, including supplements for weight loss, sexual health, and general vitality. The company faces challenges typical of shell companies and OTC-listed entities.
What Is the Investment Thesis for UMAX?
Investing in UMAX Group Corp. presents a high-risk, high-reward scenario given its status as a development stage company operating in the competitive nutritional supplement industry. With a negative profit margin of -848.0% and a negative gross margin of -118.8%, the company's financial performance raises concerns about its ability to achieve profitability. The company's high beta of 5.85 indicates significant volatility compared to the market. Key catalysts include successful product development and market penetration, while risks include intense competition, regulatory hurdles, and the challenges inherent in operating as a shell company on the OTC market. Investors should carefully consider these factors before investing in UMAX.
Based on FMP financials and quantitative analysis
UMAX Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- P/E ratio of -0.15 reflects the company's current lack of profitability.
- Profit margin of -848.0% highlights significant losses and operational inefficiencies.
- Gross margin of -118.8% indicates that the cost of goods sold exceeds revenue, posing a serious challenge to the company's business model.
- Beta of 5.85 suggests high volatility compared to the overall market, making it a higher-risk investment.
Who Are UMAX's Competitors?
UMAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UMAX's Key Strengths?
Focus on natural and organic ingredients.
- Specific product offerings targeting niche health needs.
- Potential for growth in the expanding nutritional supplement market.
- Established presence in the online retail channel.
What Are UMAX's Weaknesses?
Limited financial resources as a development stage company.
- Negative profit and gross margins.
- High beta indicating significant volatility.
- Dependence on a limited product line.
What Could Drive UMAX Stock Higher?
Potential for new product launches in the natural and organic supplement market.
- Increasing consumer demand for health and wellness products.
- Strategic partnerships with distributors and retailers to expand market reach.
What Are the Key Risks for UMAX?
Financial-distress signal — its Altman Z-Score of -8.40 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the nutritional supplement industry.
- Regulatory scrutiny and compliance requirements for dietary supplements.
- Limited financial resources as a development stage company.
- Negative profit and gross margins.
- High beta indicating significant volatility.
What Are the Growth Opportunities for UMAX?
- Expansion of Product Line: UMAX can expand its product line to include a wider range of supplements targeting different health needs. The global dietary supplements market is projected to reach $230.73 billion by 2027, offering significant growth potential. Successful product diversification could attract new customers and increase revenue streams, but requires investment in R&D and marketing.
- Strategic Partnerships: Forming strategic partnerships with established retailers or distributors can provide UMAX with access to a broader customer base and distribution network. Collaborations with health and wellness influencers can also enhance brand awareness and credibility. These partnerships can accelerate market penetration and reduce marketing costs, with potential impact within the next 1-2 years.
- E-commerce Expansion: Investing in e-commerce capabilities and online marketing can enable UMAX to reach a global audience and capitalize on the growing trend of online shopping for health and wellness products. A strong online presence can enhance brand visibility, drive sales, and improve customer engagement. This initiative can yield results within 6-12 months with focused digital marketing campaigns.
- Targeted Marketing Campaigns: Implementing targeted marketing campaigns focused on specific customer segments and health needs can improve brand awareness and drive sales. These campaigns can leverage social media, search engine optimization, and content marketing to reach potential customers. Effective marketing can increase customer acquisition and retention rates, with measurable impact within 3-6 months.
- Geographic Expansion: Expanding into new geographic markets can provide UMAX with access to a larger customer base and diversify its revenue streams. Emerging markets in Asia and Latin America offer significant growth opportunities for nutritional supplements. Successful geographic expansion requires careful market research, regulatory compliance, and adaptation to local consumer preferences, with potential for long-term growth over the next 3-5 years.
What Are UMAX's Competitive Advantages?
- Proprietary formulations of natural and organic supplements.
- Brand recognition and customer loyalty in niche markets.
- Strategic partnerships with distributors and retailers.
- Focus on specific health needs and dietary preferences.
What Does UMAX Do?
UMAX Group Corp., founded in 2011 and based in Los Angeles, California, operates as UMAX Nutrition, focusing on the development and distribution of natural and organic nutrition and dietary supplements. As a development stage company, UMAX Nutrition aims to cater to the nutritional needs of consumers through a range of products targeting various health and wellness areas. The company's product line includes supplements designed for weight loss, colon health, sexual health, body building, and general health and vitality. UMAX Nutrition's product offerings include UPRITE XXL, a natural herbal male enhancement supplement marketed as an alternative to prescription erectile dysfunction medications. Additionally, the company offers green coffee bean extract and RASPBERRY KETONE, both known for their anti-oxidant and fat-burning properties. These products reflect the company's focus on providing natural and organic solutions to meet consumer demand in the health and wellness market. UMAX Group Corp. operates within the broader nutritional supplement industry, which is characterized by increasing consumer awareness of health and wellness, driving demand for natural and organic products. However, as a development stage company, UMAX faces challenges related to product development, marketing, distribution, and competition from established players in the industry. The company's success depends on its ability to effectively market its products, establish a strong brand presence, and navigate the regulatory landscape governing the sale of dietary supplements.
What Products and Services Does UMAX Offer?
- Develops and distributes natural and organic nutrition and dietary supplements.
- Offers products for weight loss, colon health, sexual health, body building, and general health.
- Markets UPRITE XXL, a natural herbal male enhancement supplement.
- Sells green coffee bean extract and RASPBERRY KETONE as anti-oxidant and fat-burning ingredients.
- Operates as a development stage company in the nutritional industry.
- Focuses on providing dietary needs to consumers through its product line.
How Does UMAX Make Money?
- Develops and formulates nutritional supplements.
- Markets and sells products directly to consumers and through distributors.
- Generates revenue through the sale of its nutritional supplements.
- Focuses on natural and organic ingredients to appeal to health-conscious consumers.
What Industry Does UMAX Operate In?
UMAX Group Corp. operates in the nutritional supplement industry, a segment experiencing growth driven by increasing consumer awareness of health and wellness. The market is highly competitive, with established players and numerous smaller companies vying for market share. Trends include a growing demand for natural and organic products, personalized nutrition, and online distribution channels. UMAX faces competition from companies with greater resources and established brands. The industry is also subject to regulatory scrutiny, requiring compliance with labeling and safety standards.
Who Are UMAX's Key Customers?
- Individuals seeking natural and organic nutritional supplements.
- Consumers interested in weight loss, colon health, and sexual health products.
- Health-conscious individuals looking for dietary supplements.
- Customers seeking alternatives to prescription medications for certain conditions.
How UMAX Group Corp. Is Valued
Relative to its peer group, UMAX's quantitative score of 40/100 is below the peer average of 63/100.
Company Profile
UMAX Group Corp. operates in the Software - Application industry within the Technology sector. It is headquartered in Los Angeles, US. The company is led by CEO Rondell Fletcher. UMAX has traded publicly since 2013.
Key Financial Metrics
Return on equity for UMAX Group Corp. stands at 29.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.4%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
UMAX Group Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.40 places it in the distress zone, a signal of elevated financial risk.
UMAX Financials
Bull Case vs Bear Case
Bull Case
- Focus on natural and organic ingredients.
- Specific product offerings targeting niche health needs.
- Potential for growth in the expanding nutritional supplement market.
- Established presence in the online retail channel.
Bear Case
- Limited financial resources as a development stage company.
- Negative profit and gross margins.
- High beta indicating significant volatility.
- Dependence on a limited product line.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
UMAX Latest News
No recent news available for UMAX.
UMAX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UMAX.
Price Targets
Wall Street price target analysis for UMAX.
UMAX MoonshotScore
What does this score mean?
The MoonshotScore rates UMAX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Gerald Edick
CEO
Gerald Edick serves as the CEO of UMAX Group Corp. His background includes experience in the nutritional supplement industry, with a focus on product development and marketing. He has been involved in the development and launch of several nutritional supplement products. His expertise lies in identifying market trends and developing products to meet consumer demand. He is responsible for the overall strategic direction and management of the company.
Track Record: Under Gerald Edick's leadership, UMAX Group Corp. has focused on developing and distributing natural and organic nutrition and dietary supplements. Key milestones include the launch of UPRITE XXL, green coffee bean extract, and RASPBERRY KETONE. His tenure has been marked by efforts to establish a presence in the competitive nutritional supplement market, although the company continues to face financial challenges.
UMAX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that UMAX Group Corp. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial reporting, making it difficult for investors to assess their financial health and operational performance. Unlike NYSE or NASDAQ-listed companies, OTC Other companies are not subject to stringent listing requirements, potentially increasing investment risk.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Company has been in operation since 2011.
- Focus on developing and distributing nutritional supplements.
- Presence in the online retail channel.
- CEO with experience in the nutritional supplement industry.
What Investors Ask About UMAX Group Corp. (UMAX) — Financial Services
What does the AI Score mean for UMAX?
UMAX holds an AI Score of 40/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. UMAX Group Corp., operating as UMAX Nutrition, is a development stage company focused on natural and organic nutrition and dietary supplements. The company's product line targets various dietary …
What does UMAX Group Corp. do?
UMAX Group Corp., operating as UMAX Nutrition, is a development stage company focused on developing and distributing natural and organic nutrition and dietary supplements. Its product line includes supplements for weight loss, colon health, sexual health, body building, and general health and vitality. The company aims to provide consumers with natural alternatives to traditional health and wellness products, operating in the competitive nutritional supplement industry.
What do analysts say about UMAX stock?
As of 2026-03-15, there is no available analyst coverage for UMAX Group Corp. given its OTC listing and micro-cap status. Key valuation metrics such as P/E ratio (-0.15), profit margin (-848.0%), and gross margin (-118.8%) indicate significant financial challenges. Investors should conduct their own thorough due diligence and consider the risks associated with investing in a development stage company with limited financial resources and high volatility (beta of 5.85).
What are the main risks for UMAX?
The main risks for UMAX Group Corp. include intense competition from established players in the nutritional supplement industry, regulatory scrutiny and compliance requirements, limited financial resources as a development stage company, negative profit and gross margins, and high volatility. As an OTC-listed company, UMAX faces additional risks related to liquidity, transparency, and potential for price manipulation. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for UMAX?
UMAX Group Corp. (UMAX) holds an AI score of 40/100 (low). Investing in UMAX Group Corp. presents a high-risk, high-reward scenario given its status as a development stage company operating in the competitive nutritional supplement industry. Not financial advice.
How frequently does UMAX data refresh on this page?
UMAX's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven UMAX's recent stock price performance?
UMAX Group Corp. (UMAX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on natural and organic ingredients. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UMAX overvalued or undervalued right now?
UMAX Group Corp. (UMAX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research UMAX before investing?
Before investing in UMAX Group Corp. (UMAX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for UMAX Group Corp.
- OTC market investments carry higher risk than exchange-listed stocks.